Leukemia Research
Volume 34, Issue 4 , Pages 420-425 , April 2010

FISH analysis in addition to G-band karyotyping: Utility in evaluation of myelodysplastic syndromes?

Received 31 July 2009 ,Revised 2 September 2009 ,Accepted 10 September 2009.

References 

  1. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma. 1995;16:247–262
  2. Parlier V, van Melle G, Beris P, Schmidt PM, Tobler A, Haller E, et al. Hematologic, clinical, and cytogenetic analysis in 109 patients with primary myelodysplastic syndrome. Prognostic significance of morphology and chromosome findings. Cancer Genet Cytogenet. 1994;78:219–231
  3. Vallespi T, Imbert M, Mecucci C, Preudhomme C, Fenaux P. Diagnosis, classification, and cytogenetics of myelodysplastic syndromes. Haematologica. 1998;83:258–275
  4. Swerdlow SHCEHN. In:  Jaffe ES,  Pileri SA,  Stein H,  Thiele J,  Vardiman JW editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC; 2008;
  5. Mufti GJ, Bennett JM, Goasguen J, Bain BJ, Baumann I, Brunning R, et al. Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica. 2008;93:1712–1717
  6. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26:4791–4797
  7. Speicher MR, Carter NP. The new cytogenetics: blurring the boundaries with molecular biology. Nat Rev Genet. 2005;6:782–792
  8. Cuneo A, Bigoni R, Cavazzini F, Bardi A, Roberti MG, Agostini P, et al. Incidence and significance of cryptic chromosome aberrations detected by fluorescence in situ hybridization in acute myeloid leukemia with normal karyotype. Leukemia. 2002;16:1745–1751
  9. Kibbelaar RE, Mulder JW, Dreef EJ, van Kamp H, Fibbe WE, Wessels JW, et al. Detection of monosomy 7 and trisomy 8 in myeloid neoplasia: a comparison of banding and fluorescence in situ hybridization. Blood. 1993;82:904–913
  10. Beyer V, Castagne C, Muhlematter D, Parlier V, Gmur J, Hess U, et al. Systematic screening at diagnosis of −5/del(5)(q31), −7, or chromosome 8 aneuploidy by interphase fluorescence in situ hybridization in 110 acute myelocytic leukemia and high-risk myelodysplastic syndrome patients: concordances and discrepancies with conventional cytogenetics. Cancer Genet Cytogenet. 2004;152:29–41
  11. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res. 2003;27:1085–1090
  12. Bernasconi P, Cavigliano PM, Boni M, Calatroni S, Klersy C, Giardini I, et al. Is FISH a relevant prognostic tool in myelodysplastic syndromes with a normal chromosome pattern on conventional cytogenetics? A study on 57 patients. Leukemia. 2003;17:2107–2112
  13. Ketterling RP, Wyatt WA, VanWier SA, Law M, Hodnefield JM, Hanson CA, et al. Primary myelodysplastic syndrome with normal cytogenetics: utility of ‘FISH panel testing’ and M-FISH. Leuk Res. 2002;26:235–240
  14. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Bigoni R, Piva N, et al. Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings. Br J Haematol. 1998;103:189–197
  15. Romeo M, Chauffaille Mde L, Silva MR, Bahia DM, Kerbauy J. Comparison of cytogenetics with FISH in 40 myelodysplastic syndrome patients. Leuk Res. 2002;26:993–996
  16. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:620–625
  17. Shaffer LGTNI. An international system for human cytogenetic nomenclature. Basel, Switzerland: Karger; 2009;
  18. Wolff DJ, Bagg A, Cooley LD, Dewald GW, Hirsch BA, Jacky PB, et al. Guidance for fluorescence in situ hybridization testing in hematologic disorders. J Mol Diagn. 2007;9:134–143
  19. West RR, Stafford DA, White AD, Bowen DT, Padua RA. Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure. Blood. 2000;95:2093–2097
  20. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  21. Niemeyer CM, Kratz CP. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia: molecular classification and treatment options. Br J Haematol. 2008;140:610–624
  22. Sasaki H, Manabe A, Kojima S, Tsuchida M, Hayashi Y, Ikuta K, et al. Myelodysplastic syndrome in childhood: a retrospective study of 189 patients in Japan. Leukemia. 2001;15:1713–1720

PII: S0145-2126(09)00473-1

doi: 10.1016/j.leukres.2009.09.013

Leukemia Research
Volume 34, Issue 4 , Pages 420-425 , April 2010

Article Tools